BeyondSpring to Participate at the 12th Annual Immuno-Oncology 360° Conference

BeyondSpring Inc. (NASDAQ: BYSI), a clinical-stage biopharmaceutical company focused on developing innovative immune-modulating therapies for cancer, has announced its participation in the 12th Annual Immuno-Oncology 360° Conference scheduled for February 10-12, 2026, in Boston, Massachusetts. The conference serves as a prominent platform for discussing advancements in immune-oncology, a field dedicated to harnessing the body's immune system to fight cancer.

Dr. Lan Huang, the Co-Founder, Chairman, and CEO of BeyondSpring, will be presenting key insights on Plinabulin, the company’s flagship asset. This therapy is positioned as a first-in-class immuno-oncology agent designed to enhance the efficacy of PD-1/PD-L1 blockade. Dr. Huang's presentation, titled "Overcoming PD-1/L1 Resistance: Translational Insights with Plinabulin," will delve into Plinabulin’s unique mechanism of action as a dendritic cell maturation agent and its role in resensitizing tumors that exhibit resistance to existing checkpoint inhibitors.

Scheduled for Wednesday, February 11, 2026, from 4:55 PM to 5:10 PM ET at the Sheraton Boston Hotel, this session falls under the "Translational Science & Biomarkers – Expanding Therapeutic Horizons" track. Following the presentation, the slides will be made available on BeyondSpring's website under the "Posters and Presentations" section, allowing stakeholders to access this valuable information.

BeyondSpring is dedicated to addressing significant unmet medical needs, with Plinabulin currently in late-stage clinical development for non-small cell lung cancer (NSCLC) and other malignancies. The company's innovative approach heralds promising opportunities in the treatment landscape of resistant tumors. For more information, visit BeyondSpring’s website or reach out through their investor and media contact details.

BeyondSpring Inc. (NASDAQ: BYSI) is poised to make significant strides in the oncology sector, particularly with its participation in the upcoming Immuno-Oncology 360° (IO360°) Conference in Boston. The focus on Plinabulin, their leading therapeutic candidate, is noteworthy not only for its clinical applications but also for its potential to reshape treatment paradigms in cancer care.

Plinabulin stands out as a first-in-class immune-modulating agent, designed to enhance PD-1/PD-L1 blockade efficacy—an important strategy for tackling tumors that exhibit resistance to conventional therapies. BeyondSpring has emphasized Plinabulin's dual functionality as both an anti-cancer agent and a dendritic cell maturation agent, potentially offering a breakthrough for patients whose tumors fail to respond to current checkpoint inhibitors.

Investors should take note of Dr. Lan Huang's upcoming presentation, which promises to shed light on Plinabulin’s distinctive mechanism of action and clinical development strategy. This presentation will not only attract attention from industry peers and potential collaborators but also serves as an important indicator of the company’s direction and strategic focus.

The positioning of BeyondSpring within the immuno-oncology space, particularly with a focus on unmet medical needs, places it in a favorable trajectory as global cancer therapies continue evolving. However, prospective investors should remain vigilant about the volatility often associated with clinical-stage biopharmaceutical companies, particularly those dependent on the successful advancement of their lead assets through rigorous clinical trials.

In summary, BeyondSpring’s innovative approach, coupled with its preparedness to engage with the scientific community at IO360°, underscores its potential as a compelling investment opportunity. A careful evaluation of the outcomes from this conference, alongside ongoing clinical developments, will be crucial for making informed investment decisions. Investors are encouraged to monitor developments closely, as advancements in Plinabulin's clinical journey could significantly impact BeyondSpring's market valuation.